Bevacizumab and Vasoconstriction
- Registration Number
- NCT00929058
- Lead Sponsor
- Radboud University Medical Center
- Brief Summary
Rationale: The introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. One of the most common side effects of angiogenesis inhibitors is hypertension. In patients treated with bevacizumab hypertension had an overall incidence up to 32%. The etiology of hypertension caused by treatment with angiogenesis inhibitors is unclear.
Objective: To study if arterial bevacizumab infusion causes acute vasoconstriction using plethysmography in healthy volunteers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
- Male 18-50 years old
- normal results of glucose, lipids and creatinine
- informed consent
Exclusion Criteria
- History of abuse of drugs or alcohol
- History of malignant disease
- First degree relatives with a history of cancer before the age of 50
- First degree relatives with a history of premature cardiovascular disease
- Current use of medication
- Clinical evidence of cardiac of pulmonary disease
- Hypertension ( systolic>140mmHg, diastolic >90mmHg)
- Diabetes mellitus
- smoking
- a history of thombosis or a family history of recurrent thrombosis
- abnormality on ECG
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Bevacizumab Bevacizumab -
- Primary Outcome Measures
Name Time Method Fore-arm vasomotor response to administered bevacizumab, expressed as percentage change in forearm blood flow ratio Infusion of bevacizumab during 6 minutes
- Secondary Outcome Measures
Name Time Method Correlation between VEGF concentrations in plasma and the vasoconstrictive response to bevacizumab Infusion of bevacizumab during 6 minutes
Trial Locations
- Locations (1)
Radboud University Nijmegen Medical Centre
🇳🇱Nijmegen, Netherlands